Publications

Publication

Abstract/Poster

2024

A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy

Journal: CPT: Pharmacometrics & Systems Pharmacology
Publication Date: 2024-10-03
DOI: 10.1002/psp4.13246
Authors: Kim J, Morales JF, Kang S, Klose M, Willcocks RJ, Daniels MJ, Belfiore-Oshan R, Walter GA, Rooney WD, Vandenborne K, Kim S.

Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool

Journal: CPT: Pharmacometrics & Systems Pharmacology
Publication Date: 2024-07-03
DOI: 10.1002/psp4.13193
Authors: Morales JF, Klose M, Hoffert Y, Podichetty JT, Burton J, Schmidt S, Romero K, O’Doherty I, Martin F, Campbell-Thompson M, Haller MJ, Atkinson MA, Kim S.

Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

Journal: Cancer Chemother Pharmacol
Publication Date: 2024-09
DOI: 10.1007/s00280-024-04679-z
Authors: Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft C.

Machine learning-driven flattening of model priors: A comparative simulation study across multiple compounds

Event: PAGE (2024) Publication Date: 2024-06-26
Link: https://www.page-meeting.org/default.asp?abstract=10858
Authors: Klose M, Thoma F, Kovar L, Huisinga W, Michelet R, Kloft C.

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Journal: European Journal of Cancer
Publication Date: 2024-04
DOI: 10.1016/j.ejca.2024.113588
Authors: Colombo I, Koster KL, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger M.

Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation

Journal: Eur J Pharm Sci
Publication Date: 2024-03-01
DOI: 10.1016/j.ejps.2023.106689
Authors: Klose M, Cristofoletti R, Silva CM, Mangal N, Turgeon J, Michaud V, Lesko LJ, Schmidt S.

2022

The Impact of UGT2B7 and CYP2D6 Gene-Drug- and CYP-mediated Drug-Drug-Interactions on Oxycodone and Oxymorphone Pharmacokinetics using PBPK Modelling.

Event: ACoP13 (2022)
Publication Date: 2022
Link: www.go-acop.org/?abstract=413
Authors: Klose M, Schmidt S, Cristofoletti R.

2021

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients

Journal: Antibiotics (Basel)
Publication Date: 2021-04-20
DOI: 10.3390/antibiotics10040468
Authors: Liebchen U, Klose M, Paal M, Vogeser M, Zoller M, Schroeder I, Schmitt L, Huisinga W, Michelet R, Zander J, Scharf C, Weinelt FA, Kloft C.

Using microdose-based activity measurement to individualise dosing of cytochrome P450 metabolised drugs: a case study with yohimbine and tamoxifen.

Event: PAGE (2021) Publication Date: 2021
Link: https://www.page-meeting.org/default.asp?abstract=9807
Authors: Michelet R, Weinelt FA, Klose M, Mc Laughlin AM, Kluwe F, Montefusco-Pereira C, Van Dyk M, Vay M, Huisinga W, Kloft C, Mikus G.